Abcam, ab258030, Human LILRB4 (ILT-3) knockout A549 cell lysate

Size: 1Kit
LILRB4 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 4 bp deletion in exon2 and 52 bp deletion in exon2.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 4 bp deletion in exon2 and 52 bp deletion in exon2.,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-LILRB4, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ILT-3 also known as Immunoglobulin-like transcript 3 is a protein predominantly expressed on dendritic cells and monocytes. It is a type I transmembrane protein belonging to the leukocyte immunoglobulin-like receptor family. The ILT-3 protein has a molecular mass of approximately 60 kDa. In addition to its presence on dendritic cells and monocytes ILT-3 can be detected in low levels on some types of macrophages. It plays a regulatory role in the immune system which can influence how the body responds to pathogens and tissue damage.
Biological function summary
ILT-3 acts as an inhibitory receptor that modulates immune responses. It is often linked with the control of T cell activation and the maintenance of immune tolerance. ILT-3 does not form part of a larger protein complex. Its inhibitory function helps in preventing overactivation of the immune system by modulating the signaling pathways necessary for immune response. This modulation occurs through ITIM (Immunoreceptor Tyrosine-based Inhibitory Motif) domains that recruit phosphatases helping in dephosphorylating key signaling proteins and aiding in downregulation of immune cell activities.
Pathways
The ILT-3 protein is involved in important immune regulatory pathways contributing significantly to the immune checkpoint pathway. It interacts with other immunoglobulin-like receptors and is known to influence pathways involving PD-1 (Programmed cell death protein 1) and CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4). By affecting these pathways ILT-3 serves as a checkpoint that ensures immune homeostasis prevents excess inflammation and influences the balance between immune activation and suppression within the body.
ILT-3 has been implicated in autoimmune diseases and transplant rejection. It helps in suppressing immune responses that can lead to conditions like rheumatoid arthritis and could negatively affect organ transplant outcomes by minimizing the chance of rejection. ILT-3's role in these conditions connects it to proteins such as HLA-G and PD-L1 which are also involved in immune modulation and contribute to disease pathogenesis. Understanding ILT-3’s role provides insights into potential therapeutic targets for these diseases.